Fortive Corporation (FTV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus sits at a manageable bar (~$0.45 adj. EPS, ~$1.07B revenue), management guided Q2 EPS to be "broadly similar" to Q1's $0.47 beat, and April was described as tracking "nicely aligned with expectations" at the May Wolfe conference. The biggest swing factor is whether AHS healthcare capital demand continues its sequential recovery as the company laps the Q2 2025 trough.

Heading into Q2 2026, Fortive's setup is modestly favorable: consensus EPS of ~$0.45 sits below management's own implied guide of "broadly similar" to Q1's $0.47 actual, creating a low bar that the company should clear absent a macro shock. Management's tone at the May 19 Wolfe Research conference was notably upbeat — CEO Soroye confirmed April came in "strong" and the company remains "firmly on track" with its full-year framework — suggesting no deterioration in business momentum since the April 30 print. Estimate revisions have been stable-to-slightly-lower since Q1 earnings (FY2026 adj. EPS consensus ~$3.00, essentially flat since the print), consistent with a reaffirm-not-raise posture that leaves room for a modest beat. The stock has lagged XLI since Q1 earnings (+7% vs. XLI +4.5% on an indexed basis), suggesting the market has not fully priced in execution of the Fortive Accelerated strategy. The key wildcard is AHS healthcare capital equipment demand: management noted "modest sequential improvement" since Q2 2025 and expects favorable year-over-year comparisons beginning in Q2 2026 as the company laps the healthcare reimbursement policy headwind — a positive inflection here could be the catalyst for a guidance raise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a low-to-moderate bar across all key metrics — adj. EPS of ~$0.45 is below management's implied guide of "broadly similar" to Q1's $0.47 actual. IOS organic growth (~4.0%) is the bigger swing factor; AHS organic growth (~2.8%) is the secondary watch item given the healthcare capex recovery narrative.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data

Table 2 — Beat/Miss History (Last 8 Quarters — Top 2 KPIs)

Adj. EPS (Diluted — Operating)

Total Revenue

Pattern: FTV has beaten on adj. EPS in 3 of the last 3 comparable quarters as New Fortive (Q3 2025, Q4 2025, Q1 2026), with an average beat of ~+11% on EPS. Revenue beats have been more modest (+1–2%), consistent with management's conservative guidance posture.

Source: Visible Alpha Consensus and Actuals Data

3. Guidance & Commentary Evolution

Key Takeaway: Guidance is unchanged since Q1 earnings — FY2026 adj. EPS reaffirmed at $2.90–$3.00, with management signaling results are trending toward the upper half. The May Wolfe conference provided a positive intra-quarter update (April tracking well), but no formal guidance revision. Tone is constructively confident without being aggressive.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since Q1 earnings — FY2026 adj. EPS consensus of ~$2.99 is essentially flat vs. the post-Q1 baseline of ~$2.99, and Q2 EPS consensus of ~$0.45 is slightly below management's implied guide. This stability reflects management's reaffirm-not-raise posture and leaves room for a modest beat-and-raise at Q2 results.

Estimates have been essentially flat since Q1 earnings, with no meaningful revision in either direction. Consensus FY2026 adj. EPS of $2.99 sits at the very top of management's $2.90–$3.00 guidance range, implying the Street expects a beat-and-raise scenario at Q2 results. The gap between Q2 consensus EPS (~$0.45 on a comparable basis) and management's implied guide (~$0.47) represents a modest cushion for a beat.

Source: Visible Alpha Consensus and Actuals Data

5. Stock Performance

Key Takeaway: FTV has outperformed the S&P 500 (+7.2% vs. SPY +3.1%) but lagged XLI (+4.5%) since Q1 earnings on April 30, 2026. The move has been driven primarily by multiple expansion (EV/EBITDA expanded from ~15.5x to ~16.5x over 6 months) rather than estimate revisions, suggesting the market is beginning to re-rate the stock on execution of the Fortive Accelerated strategy — but the re-rating remains incomplete relative to the quality of the business model.

FTV vs. XLI vs. S&P 500 — Indexed Performance Since Q1 2026 Earnings (April 30, 2026). Source: Yahoo Finance / Stock Price Data.

Since Q1 2026 earnings on April 30, FTV has delivered a total return of approximately +7.2% (indexed to 100 at earnings date), outpacing the S&P 500 (+3.1%) but lagging the XLI Industrials ETF (+4.5%). The stock initially traded sideways through mid-May as the market digested the reaffirm-not-raise guidance posture, then re-accelerated in late June and July as industrial sentiment improved broadly. The 12-month performance of +24.4% has been driven by a combination of earnings growth (~18% adj. EPS growth) and modest multiple expansion (NTM P/E from ~18.9x to ~20.1x), with the stock now trading at 20.1x NTM EPS — still a discount to high-quality industrial peers, suggesting further re-rating potential if Q2 results confirm the growth acceleration thesis.

Valuation Context: FTV currently trades at 16.5x NTM EV/EBITDA and 20.1x NTM P/E. The 6-month multiple expansion of ~+6.4% on EV/EBITDA reflects growing confidence in the Fortive Accelerated strategy, but the stock remains at a discount to the quality of its recurring revenue base (~50% of revenue) and margin profile (30%+ adj. EBITDA margins).

Source: Yahoo Finance Stock Price Data; Visible Alpha Consensus Data

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the $1.1B notes offering completed May 14 to refinance debt at favorable rates, which reduces interest expense risk and supports the buyback program. Management's May 19 Wolfe conference commentary confirming April momentum is the key positive read-through for Q2.

• May 19, 2026 — Wolfe Research Conference (Positive): CEO Soroye confirmed April came in "strong" and "nicely aligned with expectations." Company remains "firmly on track" with FY2026 guide. Middle East (Fluke/ISC) seeing "really strong order growth." Corporate cost line running sustainably below prior guide (~$27M/qtr vs. $125–130M/yr). Implication: Positive intra-quarter read-through; no deterioration in business momentum post-Q1.
• May 14, 2026 — $1.1B Notes Offering Completed (Positive): Fortive completed a $1.1 billion senior notes offering to refinance existing debt. Implication: Reduces refinancing risk, locks in favorable rates, and supports capital return capacity. Full-year net interest expense guided to "just over $135M."
• June 11, 2026 — Annual Meeting (Neutral): Shareholders approved all proposals at the annual meeting. No material governance changes. Implication: Routine; no impact on near-term earnings.
• April 30, 2026 — Q1 2026 Earnings (Positive Setup): Q1 beat on revenue (+2.3%) and adj. EPS (+6.1%). Orders grew faster than revenue across both segments. FY2026 guidance reaffirmed with results trending toward upper half. Implication: Sets a constructive tone heading into Q2; management's conservative posture leaves room for a beat-and-raise.
• Ongoing — Tariff Countermeasures (Neutral-to-Positive): Tariffs remain a gross margin headwind (~100 bps) but are fully countermeasured at the bottom line. Management expects the headwind to dissipate partway through Q3 as countermeasures are fully lapped. Implication: Q2 still carries the gross margin drag, but the trajectory is improving and the EPS impact is neutral.
• Ongoing — Healthcare Capital Recovery (Key Watch Item): Hospital capital spending has shown "modest sequential improvement" since Q2 2025 trough. Management expects favorable YoY comparisons beginning in Q2 2026 as the company laps the healthcare reimbursement policy headwind. Implication: A positive inflection in AHS capital equipment demand could be the catalyst for a guidance raise at Q2 results.
• Ongoing — Data Center Opportunity (Positive): Fluke's CertiFiber Max (data center testing solution) continues to exceed expectations, driving pull-through of other Fluke products. Company investing in commercial expertise in data centers, defense, and distributed energy. Implication: Structural tailwind for IOS segment; data center lifecycle opportunity (O&M phase) is a multi-year growth driver.

7. Peer Commentary Read-Through (Last 60 Days — Q2 2026 Forward Outlook Only)

Key Takeaway: Peer commentary from Q2 2026 earnings reports (Teledyne, Danaher, Xylem, Rockwell) is broadly constructive for FTV's Q2 setup: industrial short-cycle demand is inflecting to mid-single-digit growth, healthcare markets are recovering, and margin expansion is achievable. The most relevant read-through is Danaher's confirmation that industrial inspection and healthcare markets "began to inflect" in Q2, directly supporting FTV's AHS recovery narrative.

Note: Only commentary from peers' Q2 2026 earnings calls and post-Q1 2026 conferences (May–July 2026) is included below. Prior-quarter retrospective commentary has been excluded.

Teledyne Technologies (TDY) — Q2 2026 Earnings (July 22, 2026)

Relevance to FTV: High — TDY's instrumentation, industrial vision, and healthcare segments overlap with FTV's IOS and AHS end markets.

• Industrial short-cycle inflection confirmed: TDY upgraded its short-cycle commercial portfolio outlook from "flat to low single digit" to "mid-single digit growth" for FY2026, citing inflection in industrial inspection and healthcare markets. Industrial and scientific vision applications grew "high single digits" (+8%) in Q2. FTV Read-Through: Supports FTV's IOS organic growth acceleration thesis; Fluke's industrial instrumentation end markets appear to be recovering.
• Healthcare demand recovering: TDY's healthcare business (X-ray sensors, radiotherapy) grew "high single digits" (+8.5%) in Q2, with "good demand" on the medical X-ray detector side. Full-year healthcare outlook is "low single digit growth." FTV Read-Through: Consistent with FTV's AHS narrative of sequential improvement; hospital capital spending recovering from 2025 trough.
• Strong book-to-bill and backlog: TDY's overall book-to-bill was 1.23x in Q2, with ~$5B funded backlog. FTV Read-Through: Positive demand signal for industrial technology companies broadly; FTV's own orders grew faster than revenue in Q1 2026.
• Margin expansion achievable: TDY delivered 120+ bps of total company margin improvement YoY, driven by revenue growth and disciplined cost control. FTV Read-Through: Validates FTV's 50–100 bps annual EBITDA margin expansion target as achievable in the current environment.
• Tariff tailwind (TDY-specific): TDY received a ~$10M tariff benefit in Q2 (mostly digital imaging), contributing ~120 bps to segment margin. FTV Read-Through: Contrast to FTV, which still faces a tariff gross margin headwind in Q2 (fully countermeasured at EPS level); TDY's experience suggests the tariff environment is manageable.

Danaher Corporation (DHR) — Q2 2026 Earnings (July 21, 2026)

Relevance to FTV: High — DHR's life sciences, diagnostics, and industrial filtration businesses share end markets with FTV's AHS segment and IOS industrial businesses.

• Industrial inspection and healthcare markets "began to inflect": DHR explicitly stated that "certain markets such as industrial inspection and health care, which had seen headwinds, were beginning to inflect" after Q1 2026. This is the most direct positive read-through for FTV's Q2 setup. FTV Read-Through: Directly supports FTV's AHS healthcare capital recovery narrative and IOS industrial instrumentation demand.
• Life sciences strongest quarter in several years: DHR's life sciences businesses experienced their "strongest quarter in several years" in Q2 2026, driven by large pharma/biopharma demand and improved biotech funding. FTV Read-Through: Positive for FTV's AHS sterilization consumables and software businesses serving healthcare providers.
• Guidance raised: DHR raised FY2026 adj. EPS guidance to $8.45–$8.60 (from $8.35–$8.55), citing Q2 beat and early Masimo acquisition close. Core revenue growth outlook maintained at 3–4% for FY2026, with Q4 exit rate expected at mid-single digits. FTV Read-Through: A peer raising guidance is a positive signal for the industrial/healthcare technology sector broadly; supports FTV's upper-half-of-range narrative.
• Microelectronics and industrial filtration strong: DHR's Pall filtration business grew ~10% in Q2, driven by microelectronics, energy, and aerospace. FTV Read-Through: Positive for FTV's Fluke data center and semiconductor testing exposure.

Xylem (XYL) — Q2 2026 Earnings (July 28, 2026)

Relevance to FTV: Moderate — XYL's industrial end markets and data center exposure provide read-through for FTV's IOS segment; less direct overlap with AHS.

• Healthy demand with book-to-bill well above 1: XYL reported ending backlog of $5.3B and book-to-bill "well above one" for Q2 2026. Applied Water orders up 9% with data center orders up "over 300%." FTV Read-Through: Broad industrial demand remains healthy; data center infrastructure investment continues to accelerate, supporting Fluke's data center testing opportunity.
• Margin expansion driven by productivity and price: XYL delivered Q2 EBITDA margin of 23.3% (+150 bps YoY), driven by productivity, price, and mix. Full-year EBITDA margin guidance raised to 23.1–23.5%. FTV Read-Through: Validates that industrial companies with pricing power can expand margins in the current environment, consistent with FTV's margin expansion framework.
• No material tariff impact: XYL stated "no material impact to our projected results from recently announced changes in tariffs or tariff refunds." FTV Read-Through: Suggests the tariff environment is manageable for diversified industrial companies; FTV's countermeasures appear well-calibrated.
• Revenue acceleration expected through year-end: XYL guided to organic growth of ~1% in Q2, ~3% in Q3, and mid-single digits in Q4, indicating building momentum. FTV Read-Through: Consistent with FTV's narrative of sequential growth acceleration through 2026.

Rockwell Automation (ROK) — Wells Fargo Conference (June 11, 2026)

Relevance to FTV: Moderate — ROK's industrial automation end markets overlap with FTV's IOS segment; ROK's software/control commentary is relevant to FTV's FAL software businesses.

• Good growth across many industries; raised FY guide to 7%: ROK raised its full-year organic growth guide to 7%, citing "good growth" in Intelligent Devices and Software & Control across many industries. Demand broadening into semiconductor, data center, e-commerce/warehouse automation, and energy. FTV Read-Through: Positive for FTV's IOS segment; data center and semiconductor end markets are accelerating, supporting Fluke's growth initiatives.
• Smaller modernization projects driving demand: ROK noted demand is concentrated in "smaller modernization projects" focused on efficiency and productivity, with larger CapEx projects still on hold due to trade uncertainty. FTV Read-Through: Positive for FTV's OpEx-oriented business model (Fluke, FAL, ISC) which benefits from maintenance/efficiency spending rather than large CapEx cycles.
• AI as automation demand propellant: ROK described AI as a "tremendous opportunity for automation" by simplifying consumption of automation technology, acting as a "significant propellant of more automation demand." FTV Read-Through: Consistent with FTV's AI-enabled product strategy (Gordian Flash, Fluke Certified Max, Provation Mira); AI is accelerating product development and customer engagement.
• Caution on large CapEx projects: ROK noted customers are "holding off on larger, longer-ranging CapEx projects" due to trade uncertainty and geopolitical volatility. FTV Read-Through: Modest negative for FTV's AHS capital equipment (sterilization systems), though management has already guided to cautious hospital capital spending and expects improvement as the company laps the 2025 trough.

8. Insider Transaction Activity

Key Takeaway: Only one open-market transaction was filed in the post-Q1 window — a discretionary open-market sale by the Chief Legal Officer on May 4, 2026. No open-market buys were filed. The absence of clustered buying or unusual selling activity is neutral; the single sale is not a meaningful signal given its discretionary nature and the CLO's remaining position of 87,780 shares.

No open-market purchases were filed by any insider in the April 30 – July 28, 2026 window. The single sale by the CLO is not unusual in size relative to his remaining position and does not represent a meaningful negative signal. The absence of insider buying is neutral given the stock's +7% post-earnings performance.

Source: SEC Form 4 Filings Database